AD Clinical Trials in Beijing, Beijing Municipality
321 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 321 trials
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled23 locationsNCT07222267
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 3
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc330 enrolled1 locationNCT06998108
Recruiting
Not Applicable
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
Breast CancerBreast MassesBreast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital500 enrolled1 locationNCT06908291
Recruiting
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences150 enrolled1 locationNCT06776861
Recruiting
Phase 2
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06667622
Recruiting
Not Applicable
Super-Hypofractionated Partial Breast Irradiation
Breast CancerRadiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT06615466
Recruiting
Not Applicable
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581
Recruiting
Phase 3
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Advanced Breast Cancer
Peking Union Medical College Hospital80 enrolled1 locationNCT05861830
Recruiting
Phase 2
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT05983107
Recruiting
Phase 2Phase 3
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Breast CancerOptical Surface Monitoring TechnologyLarge-segment Radiotherapy
Peking Union Medical College Hospital556 enrolled1 locationNCT05804916